Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Probelte Pharma S.L.
Sponsor

Probelte Pharma S.L.

Spain Calle Antonio Belmonte Abellan 7, 30100 Murcia, Spain

About the sponsor

Probelte Pharma S.L. focuses on allergen immunotherapy for allergic rhinoconjunctivitis, with research centered on grass pollen and house dust mite sensitisation. Its clinical programme includes subcutaneous immunotherapy approaches for patients with respiratory allergy symptoms linked to environmental allergens.

  • Grass pollen allergy
  • House dust mite allergy
  • Allergic rhinoconjunctivitis

The sponsor’s trials also address patients with allergic rhinoconjunctivitis associated with asthma, reflecting interest in upper and lower airway allergic disease.

About Specializations

Probelte Pharma S.L. runs clinical trials in conditions such as Mite allergy, Seasonal allergy, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

5 clinical trials

Mite allergy

Recruiting
Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Mixture Of Allergen Extracts Of Dermatophagoides Pteronyssinus And Dermatophagoides Farinae Polymerized With Glutaraldehyde
  • Sponsor:Probelte Pharma S.L.

Seasonal allergy

Not yet recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Placebo
  • Sponsor:Probelte Pharma S.L.

Mite allergy

Not yet recruiting
Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLERGEN EXTRACTS
  • Sponsor:Probelte Pharma S.L.

Mite allergy

Not yet recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Dermatophagoides Farinae
  • Sponsor:Probelte Pharma S.L.

Seasonal allergy

Not yet recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Probelte Pharma S.L.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).